阿普塔默研究和未来应用的进展
Song Liu1, Xiaolu Li1, Huyang Gao2
1Beijing Anzhen Hospital, Capital Medical University, Experimental Research Center, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, China.
ChemistryOpen
|February 4, 2025
概括
短核酸序列的aptamers为诊断和治疗的抗体提供了一个有希望的替代品. 本综述强调了在aptamer生成,查和临床应用方面的进展,同时也解决了当前的挑战.
科学领域:
- 生物技术和分子生物学
- 核酸治疗药物 核酸治疗药物
- 诊断发展 诊断发展
背景情况:
- 胺是单链DNA,RNA或合成XNA分子,具有高特异性和对目标分子的亲和力.
- 它们在各种生物应用中作为抗体的可行替代品.
- 亚胺在诊断,向药物输送和疾病治疗方面显示出显著的潜力.
研究的目的:
- 审查最近在阿普坦技术的进步.
- 为了强调aptamer的生成,查和多样化的应用.
- 讨论在阿普他默研究和临床使用方面的挑战和未来方向.
主要方法:
- 该审查侧重于指数级丰富联结体 (SELEX) 过程的系统演变,用于体鉴定.
- 它检查了胺基生成和查的各个阶段.
- 关于aptamer应用和临床翻译的当前研究的文献综述.
主要成果:
- 胺剂在基础研究和临床诊断中越来越多地被使用.
- 在开发用于治疗应用的aptamer方面取得了重大进展.
- 该综述涵盖了小分子体及其发展的进展.
结论:
- 亚胺体现了一个快速发展的领域,在医学和研究中具有广泛的潜力.
- 需要进一步的研究,以克服现有的挑战,以实现更广泛的临床采用.
- 在aptamer生成和应用开发方面持续创新至关重要.
相关概念视频
Next-generation Sequencing
87.2K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
87.2K
Sanger Sequencing
752.6K
DNA sequencing is a fundamental technique that is routinely used in the biological sciences. This method can be applied to a range of questions at different scales - from the sequencing of a cloned DNA fragment or the study of a mutation in a gene up to whole-genome sequencing. However, despite the widespread use of sequencing today, it was not until 1977 that Fredrick Sanger and his collaborators developed the chain-termination method to decode DNA sequences. It relies on the separation of a...
752.6K


